ADAPTIMMUNE THERAPEUTICS PLC
NASDAQ: ADAP (Adaptimmune Therapeutics plc)
Last update: 12 hours ago0.253
0.00 (-0.32%)
| Previous Close | 0.254 |
| Open | 0.250 |
| Volume | 458,179 |
| Avg. Volume (3M) | 1,438,296 |
| Market Cap | 67,058,152 |
| Price / Sales | 0.360 |
| Price / Book | 2.68 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 16 Aug 2025 |
| Profit Margin | -38.91% |
| Operating Margin (TTM) | -604.96% |
| Diluted EPS (TTM) | -0.300 |
| Quarterly Revenue Growth (YOY) | 28.30% |
| Total Debt/Equity (MRQ) | 626.29% |
| Current Ratio (MRQ) | 2.02 |
| Operating Cash Flow (TTM) | -107.85 M |
| Levered Free Cash Flow (TTM) | -30.50 M |
| Return on Assets (TTM) | -14.19% |
| Return on Equity (TTM) | -275.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Adaptimmune Therapeutics plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 44.16% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 3.00 (HC Wainwright & Co., 1,085.77%) | Buy |
| Median | 1.38 (445.46%) | |
| Low | 0.460 (Barclays, 81.82%) | Sell |
| Average | 1.55 (512.65%) | |
| Total | 2 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 0.256 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 14 May 2025 | 0.460 (81.82%) | Sell | 0.272 |
| Wells Fargo | 14 May 2025 | 1.00 (295.26%) | Hold | 0.272 |
| HC Wainwright & Co. | 01 Apr 2025 | 3.00 (1,085.77%) | Buy | 0.250 |
| Guggenheim | 26 Mar 2025 | 1.75 (591.70%) | Buy | 0.230 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 May 2025 | Announcement | Adaptimmune Reports Q1 Financial Results and Provides Business Update |
| 07 May 2025 | Announcement | Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |